Fig. 5: αPD1 can control the growth of tumors that progress despite αVEGF treatment in mouse schwannoma models. | Nature Communications

Fig. 5: αPD1 can control the growth of tumors that progress despite αVEGF treatment in mouse schwannoma models.

From: NKG2D upregulation sensitizes tumors to combined anti-PD1 and anti-VEGF therapy and prevents hearing loss

Fig. 5

A Graphic depicting the timeline of αVEGF and αPD1 treatment in the Nf2−/− CPA and SN models. The schematic in panel A was created in BioRender. Xu, L. (2026) http://BioRender.com/twbqhmz. B In the SN model, tumor diameter was measured by caliper every 3 days. N = 24 mice/group. C Kaplan-Meier survival curve of mice bearing Nf2−/− tumor in the CPA model. *P = 0.0001. N = 24 mice/group. D ABR threshold of mice bearing Nf2−/− tumor in the CPA model. αVEGF + αPD1 vs. switch to αPD1: 8.0 kHz: P = 0.018, 11.33 kHz: P = 0.005, 16.0 kHz: P = 0.003, 22.65 kHz: P = 0.003, 32.0 kHz: P = 0.031, 45.25 kHz: P = 0.005. N = 18 mice/group. E Flow cytometry analysis of the number of CD8+ T cells, NK cells, and MDSC in Nf2−/− tumors from αVEGF alone (n = 10), Switch to αPD1 (n = 10), αVEGF +  αPD1 (n = 10). Flow cytometry studies are presented as mean ± SD, with significance analyzed by two-sided Student’s t test and the Mann-Whitney U test. Animal experiments are graphed as mean ± SEM. Graphs are representative examples of at least three independent experiments. Differences in sciatic nerve tumor growth were analyzed using repeated-measures two-way ANOVA. Kaplan-Meier survival curves were analyzed by the Log-rank (Mantel-Cox) test. ABR thresholds were analyzed with a linear mixed-effects model. Source data are provided as a Source Data file.

Back to article page